Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pinaki Biswas

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Immunotherapy|November 15, 2021
Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summaryThomas Bieber, Eric L Simpson, Jonathan I Silverberg, et al.
The New England Journal of Medicine|March 24, 2021
Abrocitinib versus Placebo or Dupilumab for Atopic DermatitisThomas Bieber, Eric L Simpson, Jonathan I Silverberg, et al.
Clinical Immunology (Orlando, Fla.)|March 9, 2018
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteersKent J Weinhold, Jack F Bukowski, Todd V Brennan, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Immunotherapy|November 15, 2021
Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summaryThomas Bieber, Eric L Simpson, Jonathan I Silverberg, et al.
The New England Journal of Medicine|March 24, 2021
Abrocitinib versus Placebo or Dupilumab for Atopic DermatitisThomas Bieber, Eric L Simpson, Jonathan I Silverberg, et al.
Clinical Immunology (Orlando, Fla.)|March 9, 2018
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteersKent J Weinhold, Jack F Bukowski, Todd V Brennan, et al.
Pageof 6